Sympathetic nervous system inhibition is a crucial therapeutic target for reducing cardiovascular risk and slowing disease progression in patients with chronic kidney disease.
Sympathetic nervous system plays a crucial role in the development of cardiovascular complications in chronic kidney disease (CKD) patients. The aim of this review is to summarize up-to-date knowledge of the sympathetic hyperactivity in the pathogenesis of CKD, its clinical relevance, and as the options of current treatment.
No takes yet. Share an insight, caveat, or question.
Natalia Stepanova (2017) conducted a review in Chronic kidney disease with sympathetic hyperactivity. Sympatholytic therapies (e.g., moxonidine, renal denervation) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: